After Biogen and Eisai’s Alzheimer’s drug showed strong results in a phase 3 trial in late September, Biogen’s shares rose 36 percent and most news outlets reported the results — but don’t get too excited about it, researchers told The Wall Street Journal.
Read the full post on Becker's Hospital Review - Healthcare News
